Regulatory T cells: What role do they play in antitumor immunity in patients with head and neck cancer?

Advances in the treatment modalities for head and neck squamous cell carcinoma (HNSCC) over the last 20 years involving surgery, radiotherapy, chemotherapy, and immunotherapy are not fully reflected in increases in the 5-year survival rates, mainly due to locoregional recurrences and to a lesser extent, distant metastasis. This can, in part, be attributed to the fact that HNSCC induces severe depression of a patient’s immune system. Recent advances in understanding the complex host–tumor interactions have led to the identification of a distinct suppressor cell population known as regulatory T cells that play a crucial role in maintaining T-cell tolerance to self-antigens. Here, we present a critical review of our understanding of the involvement of regulatory T cells in controlling the T-cell immune response in tumor occurrence and progression in HNSCC with an emphasis on current and future immunotherapeutic approaches involving regulatory T cells. VC 2008 Wiley Periodicals, Inc. Head Neck 30: 251–261, 2008

[1]  J. Greenman,et al.  Investigation of interleukin 10, 12 and 18 levels in patients with head and neck cancer. , 2007, The Journal of laryngology and otology.

[2]  T. Whiteside,et al.  Relationships between regulatory T cells and CD8+ effector populations in patients with squamous cell carcinoma of the head and neck , 2007, Head & neck.

[3]  T. Whiteside,et al.  Selective Survival of Naturally Occurring Human CD4+CD25+Foxp3+ Regulatory T Cells Cultured with Rapamycin1 , 2007, The Journal of Immunology.

[4]  N. Hayashi,et al.  Natural killer cell and hepatic cell interaction via NKG2A leads to dendritic cell‐mediated induction of CD4+ CD25+ T cells with PD‐1‐dependent regulatory activities , 2007, Immunology.

[5]  H. Weiner,et al.  Th3 Cells in Peripheral Tolerance. I. Induction of Foxp3-Positive Regulatory T Cells by Th3 Cells Derived from TGF-β T Cell-Transgenic Mice1 , 2007, The Journal of Immunology.

[6]  A. Banham Cell-surface IL-7 receptor expression facilitates the purification of FOXP3(+) regulatory T cells. , 2006, Trends in immunology.

[7]  Emili Montserrat,et al.  High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. , 2006, Blood.

[8]  H. Fujii,et al.  CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers , 2006, Cancer Immunology, Immunotherapy.

[9]  H. Weiner,et al.  TGF-β-Mediated Suppression by CD4+CD25+ T Cells Is Facilitated by CTLA-4 Signaling , 2006, The Journal of Immunology.

[10]  Z. Tian,et al.  The regulatory effect of natural killer cells: do "NK-reg cells" exist? , 2006, Cellular & molecular immunology.

[11]  W. Zou,et al.  Regulatory T-cell compartmentalization and trafficking. , 2006, Blood.

[12]  T. Gingeras,et al.  CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells , 2006, The Journal of experimental medicine.

[13]  G. Zhu,et al.  Cutting Edge: Induction of B7-H4 on APCs through IL-10: Novel Suppressive Mode for Regulatory T Cells1 , 2006, The Journal of Immunology.

[14]  M. Young,et al.  Protective mechanisms of head and neck squamous cell carcinomas from immune assault , 2006, Head & neck.

[15]  W. Zou Regulatory T cells, tumour immunity and immunotherapy , 2006, Nature Reviews Immunology.

[16]  T. Whiteside,et al.  Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. , 2006, Seminars in cancer biology.

[17]  T. Whiteside,et al.  Maturation of circulating dendritic cells and imbalance of T-cell subsets in patients with squamous cell carcinoma of the head and neck , 2006, Cancer Immunology, Immunotherapy.

[18]  E. Gilboa,et al.  Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. , 2005, The Journal of clinical investigation.

[19]  T. Curiel,et al.  Regulatory T Cells in Ovarian Cancer: Biology and Therapeutic Potential , 2005, American journal of reproductive immunology.

[20]  T. Nomura,et al.  Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells , 2005, The Journal of experimental medicine.

[21]  D. Linehan,et al.  CD25+CD4+ regulatory T-cells in cancer , 2005, Immunologic research.

[22]  R. Ferris,et al.  Immune responses to p53 in patients with cancer:enrichment in tetramer+ p53 peptide-specific T cells and regulatory T cells at tumor sites , 2005, Cancer Immunology, Immunotherapy.

[23]  C. N. Coleman,et al.  The Requirement of Multimodal Therapy (Vaccine, Local Tumor Radiation, and Reduction of Suppressor Cells) to Eliminate Established Tumors , 2005, Clinical Cancer Research.

[24]  S. Lira,et al.  Lymph Node Occupancy Is Required for the Peripheral Development of Alloantigen-Specific Foxp3+ Regulatory T Cells1 , 2005, The Journal of Immunology.

[25]  K. Bartels,et al.  A local enrichment of regulatory T cells within the tumor tissue might suppress an effective anti-tumor T cell response in patients with head and neck cancer , 2005 .

[26]  S. Chattopadhyay,et al.  Regulatory T cells and tumor immunity , 2005, Cancer Immunology, Immunotherapy.

[27]  S. Sakaguchi Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self , 2005, Nature Immunology.

[28]  J. Schlom,et al.  Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. , 2005, Blood.

[29]  R. Schwartz,et al.  Natural regulatory T cells and self-tolerance , 2005, Nature Immunology.

[30]  H. Boehmer,et al.  Mechanisms of suppression by suppressor T cells , 2005, Nature Immunology.

[31]  C. Baecher-Allan,et al.  Functional analysis of highly defined, FACS-isolated populations of human regulatory CD4+CD25+ T cells. , 2005, Clinical immunology.

[32]  Giovanna Roncador,et al.  Outcome in Hodgkin's Lymphoma Can Be Predicted from the Presence of Accompanying Cytotoxic and Regulatory T Cells , 2005, Clinical Cancer Research.

[33]  David C. Gondek,et al.  Cutting Edge: Contact-Mediated Suppression by CD4+CD25+ Regulatory Cells Involves a Granzyme B-Dependent, Perforin-Independent Mechanism1 , 2005, The Journal of Immunology.

[34]  R. Bonasio,et al.  Bone marrow is a major reservoir and site of recruitment for central memory CD8+ T cells. , 2005, Immunity.

[35]  E. Wherry,et al.  Bone Marrow Is a Preferred Site for Homeostatic Proliferation of Memory CD8 T Cells , 2005, The Journal of Immunology.

[36]  F. Ronchese,et al.  Dendritic Cells Loaded with Stressed Tumor Cells Elicit Long-Lasting Protective Tumor Immunity in Mice Depleted of CD4+CD25+ Regulatory T Cells1 , 2005, The Journal of Immunology.

[37]  P. Hillsamer,et al.  Regulatory T cells can migrate to follicles upon T cell activation and suppress GC-Th cells and GC-Th cell-driven B cell responses. , 2004, The Journal of clinical investigation.

[38]  Brian Barnett,et al.  Bone Marrow Is a Reservoir for CD4+CD25+ Regulatory T Cells that Traffic through CXCL12/CXCR4 Signals , 2004, Cancer Research.

[39]  J. Bluestone,et al.  Distinct roles of CTLA‐4 and TGF‐β in CD4+CD25+ regulatory T cell function , 2004 .

[40]  C. Drake,et al.  Role of LAG-3 in regulatory T cells. , 2004, Immunity.

[41]  S. Rosenberg,et al.  Cancer immunotherapy: moving beyond current vaccines , 2004, Nature Medicine.

[42]  E. Shevach Regulatory/suppressor T cells in health and disease. , 2004, Arthritis and rheumatism.

[43]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[44]  Lieping Chen,et al.  Co-signaling molecules of the B7-CD28 family in positive and negative regulation of T lymphocyte responses. , 2004, Microbes and infection.

[45]  R. Ferris,et al.  Decreased Absolute Counts of T Lymphocyte Subsets and Their Relation to Disease in Squamous Cell Carcinoma of the Head and Neck , 2004, Clinical Cancer Research.

[46]  T. Whiteside Down-regulation of ζ-chain expression in T cells: a biomarker of prognosis in cancer? , 2004, Cancer Immunology, Immunotherapy.

[47]  J. Berzofsky,et al.  Immunoregulatory T cells in tumor immunity. , 2004, Current opinion in immunology.

[48]  C. Riccardi,et al.  Frontline: GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations , 2004, European journal of immunology.

[49]  A. Fattorossi,et al.  Lymphocyte populations in human lymph nodes. Alterations in CD4+ CD25+ T regulatory cell phenotype and T‐cell receptor Vβ repertoire , 2003, Immunology.

[50]  H. Fujii,et al.  Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[51]  F. Ramsdell,et al.  Foxp3 and natural regulatory T cells: key to a cell lineage? , 2003, Immunity.

[52]  L. Klein,et al.  In vivo dynamics of antigen-specific regulatory T cells not predicted from behavior in vitro , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[53]  Thomas A. Davis,et al.  Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[54]  Thomas Davis,et al.  Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[55]  J. Longmate,et al.  CTLA-4 Blockade Enhances the Therapeutic Effect of an Attenuated Poxvirus Vaccine Targeting p53 in an Established Murine Tumor Model1 , 2003, The Journal of Immunology.

[56]  A. Rudensky,et al.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells , 2003, Nature Immunology.

[57]  T. Nomura,et al.  Control of Regulatory T Cell Development by the Transcription Factor Foxp3 , 2003 .

[58]  M. Steurer,et al.  Increase of regulatory T cells in the peripheral blood of cancer patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[59]  S. Ferrone,et al.  HLA class I antigen loss, tumor immune escape and immune selection. , 2002, Vaccine.

[60]  E. Remmerswaal,et al.  Proliferation Requirements of Cytomegalovirus-Specific, Effector-Type Human CD8+ T Cells1 , 2002, The Journal of Immunology.

[61]  J. Lafaille,et al.  Interleukin 2 Signaling Is Required for CD4+ Regulatory T Cell Function , 2002, The Journal of experimental medicine.

[62]  T. Eberlein,et al.  Prevalence of Regulatory T Cells Is Increased in Peripheral Blood and Tumor Microenvironment of Patients with Pancreas or Breast Adenocarcinoma1 , 2002, The Journal of Immunology.

[63]  Y. Tokura,et al.  Interleukin‐10 expressed at early tumour sites induces subsequent generation of CD4+ T‐regulatory cells and systemic collapse of antitumour immunity , 2001, Immunology.

[64]  E. Shevach,et al.  Cutting Edge: Control of CD8+ T Cell Activation by CD4+CD25+ Immunoregulatory Cells , 2001, The Journal of Immunology.

[65]  M. Salmon,et al.  Human anergic/suppressive CD4+CD25+ T cells: a highly differentiated and apoptosis‐prone population , 2001, European journal of immunology.

[66]  D. Mason,et al.  Human CD4+CD25+ thymocytes and peripheral T cells have immune suppressive activity in vitro , 2001, European journal of immunology.

[67]  S. Sakaguchi Regulatory T cells , 2006, Springer Seminars in Immunopathology.

[68]  J. Shimizu,et al.  Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. , 1999, Journal of immunology.

[69]  T. Fujita,et al.  Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. , 1999, Cancer research.

[70]  J. Johnson,et al.  Spontaneous ex vivo apoptosis of peripheral blood mononuclear cells in patients with head and neck cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[71]  J. Johnson,et al.  Clinical significance of decreased zeta chain expression in peripheral blood lymphocytes of patients with head and neck cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[72]  B. Melichar,et al.  Lineage-negative human leukocyte antigen-DR+ cells with the phenotype of undifferentiated dendritic cells in patients with carcinoma of the abdomen and pelvis. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[73]  D. Carbone,et al.  Decreased antigen presentation by dendritic cells in patients with breast cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[74]  M. Young,et al.  Mechanisms of immune suppression in patients with head and neck cancer: Influence on the immune infiltrate of the cancer , 1996, International journal of cancer.

[75]  M. Toda,et al.  Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. , 1995, Journal of immunology.

[76]  A. Katz,et al.  Update on immunology of head and neck cancer. , 1993, The Medical clinics of North America.

[77]  R. North,et al.  T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor , 1980, The Journal of experimental medicine.

[78]  R. Ferris,et al.  Imbalance in absolute counts of T lymphocyte subsets in patients with head and neck cancer and its relation to disease. , 2005, Advances in oto-rhino-laryngology.

[79]  T. Whiteside Immunobiology of head and neck cancer , 2005, Cancer and Metastasis Reviews.

[80]  A. Foussat,et al.  A Comparative Study between T Regulatory Type 1 and CD4 CD25 T Cells in the Control of Inflammation , 2003 .

[81]  P. Rodriguez,et al.  Mechanisms of tumor evasion from the immune response. , 2003, Cancer chemotherapy and biological response modifiers.

[82]  I. Melero,et al.  CD4 /CD25 Regulatory Cells Inhibit Activation of Tumor-Primed CD4 T Cells with IFN- -Dependent Antiangiogenic Activity, as well as Long-Lasting Tumor Immunity Elicited by Peptide Vaccination , 2003 .

[83]  E. Shevach Regulatory T cells in autoimmmunity*. , 2000, Annual review of immunology.

[84]  B. Wollenberg,et al.  Impairment of T-cell activation in head and neck cancer in situ and in vitro: strategies for an immune restoration. , 1999, Archives of otolaryngology--head & neck surgery.